News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure at the threshold of a breakthrough in the treatment of inflammatory and fibrotic diseases. The focus on the most breakthrough therapy and the OATD-01 and OATD-02 clinical trials results in a reduction of programs in the discovery phase from five to three

15 October 2024

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors

15 October 2024

Invitation to investor meeting 16th October 2024, 10:00 am (CET)

14 October 2024

Molecure has released its financial report for the first half of 2024. The company continues to develop innovative therapies in the fight against oncological and inflammatory-fibrotic diseases

27 September 2024

Invitation to investor meeting 1st October 2024, 2:00 pm (CET)

23 September 2024

Dr Piotr Iwanowski appointed as Chief Medical Officer and Board Member of Molecure

1 August 2024

Events & Presentations

EFMC – International Symposium on Medicinal Chemistry – Ljubljana 02-06.09.2018

17 September 2018

ERS International Congress 2018 – Paris, France 15-19.09.2018

14 September 2018

54th International Conference on Medicinal Chemistry, Strasbourg, France – July 4-6, 2018.

17 July 2018

ATS 2018, 18 – 23 May, San Diego, USA

21 May 2018

ESMO Immuno Oncology Congress Geneva – December 7-10

1 December 2017

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017

1 October 2017